06/17/2026
Today, uniQure announced that the FDA will allow the 3-year Phase 1/2 trial data to serve as the primary basis for a Biologics License Application (BLA) for accelerated approval. The FDA will also work with uniQure on a study design to including alternatives to a sham brain surgery.
Your voices made a difference. The FDA listened. YOU did this